The short version

From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.

  • Align Technology is the larger company, worth $9.9B, about 1.6 times Bausch + Lomb.
  • Bausch + Lomb grew revenue faster over the last year (+9.1% vs +4.3%).
  • Align Technology keeps more of each dollar of revenue as operating profit (13.2% vs 6.1%).

Side by side

The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.

MeasureALGNBLCO
Market cap$9.9B$6.1B
Share price$142.71$17.30
Revenue (last fiscal year)$4.0B$5.1B
Free cash flow (last fiscal year)$491M-$66M
Revenue growth, last year+4.3%+9.1%
Revenue growth per year, last 5 fiscal years+0.5%+7.9%
Operating margin13.2%6.1%
Net margin10.0%-3.2%
Return on equity9.8%-2.7%
P/E (trailing)23.4x—
Price / free cash flow20.2x—
EV / EBITDA11.9x14.9x
FCF growth the price implies5.2%—
Dividend yield——
Debt / equity0.52x1.16x
Fundamental gradeCD
Superinvestors holding it30
Insider purchases, last 12 months03

Results from SEC filings

Revenue and free cash flow by fiscal year, from each company's 10-K filings.

Align Technology

YearRevenueFree cash flowOp. margin
2021$4.0B$771M24.7%
2022$3.7B$277M17.2%
2023$3.9B$608M16.7%
2024$4.0B$623M15.2%
2025$4.0B$491M13.5%

Bausch + Lomb

YearRevenueFree cash flowOp. margin
2021$3.8B$680M8.7%
2022$3.8B$170M5.5%
2023$4.1B-$198M3.1%
2024$4.8B-$59M3.4%
2025$5.1B-$66M2.2%

Where the revenue comes from

Align Technology · by segments, 2025

Clear Aligner$3.2B80%
Systems and Services$790M20%

Bausch + Lomb · by segments, 2025

Vision Care$2.9B57%
Pharmaceuticals$1.3B25%
Surgical$894M18%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open ALGN in Investingly

Questions

Which is bigger, Align Technology or Bausch + Lomb?

Align Technology (ALGN), at $9.9B against $6.1B.

Which grows faster, ALGN or BLCO?

Bausch + Lomb: revenue grew +9.1% over the last year, against +4.3%.

Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.